C5AR1 and diabetic kidney disease: The promising results observed with peptide-based C5aR1 inhibitors in preclinical disease models, in addition to the safety and tolerability of PMX53 and PMX205 validated in Phase I trials, highlight the potential to advance these inhibitors into clinical practice for the treatment of various inflammatory conditions, perhaps including DKD.